
Fate Therapeutics’ iPSC-derived CAR-T FT819 Nabs FDA RMAT Designation for Lupus
Fate Therapeutics’ FT819, an investigational allogeneic induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor T-cell (CAR-T) therapy, has garnered regenerative medicine advanced therapy (RMAT) designation from the FDA for active moderate …